Prevention and Reduction of AD‐type Pathology in PDAPP Mice Immunized with Aβ1–42
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
A bstract: In AD certain brain structures contain a pathological density of Aβ protein deposited into plaques. The effect of genetic mutations found in early onset AD patients was an overproduction of Aβ 42, strongly suggesting that overproduction of Aβ 42 is associated with AD. We hypothesized that an immunological response to Aβ 42 might alter its turnover and metabolism. Young PDAPP transgenic mice were immunized with Aβ 1–42, which essentially prevented amyloid deposition; astrocytosis was dramatically reduced and there was reduction in Aβ‐induced inflammatory response as well. Aβ 1–42 immunization also appeared to arrest the progression of amyloidosis in older PDAPP mice. Aβ immunization appears to increase clearance of amyloid plaques, and may therefore be a novel and effective approach for the treatment of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599
CSF markers for incipient Alzheimer's disease
Blennow, K., & Hampel, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00530-1 · Cited by 1,291
Apolipoprotein E in sporadic Alzheimer's disease: Allelic variation and receptor interactions
William Rebeck, G., Reiter, J. S., Strickland, D. K., & Hyman, B. T. (1993) · Neuron · doi:10.1016/0896-6273(93)90070-8 · Cited by 1,107
Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition
Bales, K. R., Verina, T., Dodel, R. C., Du, Y., Altstiel, L., Bender, M., Hyslop, P., Johnstone, E. M., Little, S. P., Cummins, D. J., et al. (1997) · Nature Genetics · doi:10.1038/ng1197-263 · Cited by 830
Cited by
Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization
Orgogozo, J.-M., Gilman, S., Dartigues, J.-F., Laurent, B., Puel, M., Kirby, L. C., Jouanny, P., Dubois, B., Eisner, L., Flitman, S., et al. (2003) · Neurology · doi:10.1212/01.wnl.0000073623.84147.a8 · Cited by 1,356
Effects of α-Synuclein Immunization in a Mouse Model of Parkinson’s Disease
Masliah, E., Rockenstein, E., Adame, A., Alford, M., Crews, L., Hashimoto, M., Seubert, P., Lee, M., Goldstein, J., Chilcote, T., et al. (2005) · Neuron · doi:10.1016/j.neuron.2005.05.010 · Cited by 542
Self-citationEnari, M., Flechsig, E., & Weissmann, C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151242598 · Cited by 427
Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD
Bayer, A. J., Bullock, R., Jones, R. W., Wilkinson, D., Paterson, K. R., Jenkins, L., Millais, S. B., & Donoghue, S. (2005) · Neurology · doi:10.1212/01.wnl.0000148604.77591.67 · Cited by 356
Consequence of Aβ immunization on the vasculature of human Alzheimer's disease brain
Boche, D., Zotova, E., Weller, R. O., Love, S., Neal, J. W., Pickering, R. M., Wilkinson, D., Holmes, C., & Nicoll, J. A. R. (2008) · Brain · doi:10.1093/brain/awn261 · Cited by 316
Metadata
- Authors
- GAMES, D., BARD, F., GRAJEDA, H., GUIDO, T., KHAN, K., SORIANO, F., VASQUEZ, N., WEHNER, N., JOHNSON‐WOOD, K., YEDNOCK, T., SEUBERT, P., & SCHENK, D.
- Venue
- Annals of the New York Academy of Sciences
- Publisher
- Wiley
- Published
- 2000-12
- Volume
- 920
- Issue
- 1
- Pages
- 274-284
- ISSN
- 0077-8923 (ISSN-L)
- 1749-6632
- OpenAlex
- W1974400147
- Cited by
- 50
- References
- 4
- FWCI
- 2.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prevention and Reduction of AD‐type Pathology in PDAPP Mice Immunized with Aβ1–42. https://app.cochat.ai/papers/10.1111/j.1749-6632.2000.tb06936.x
- The paper
- GAMES, D., BARD, F., GRAJEDA, H., GUIDO, T., KHAN, K., SORIANO, F., VASQUEZ, N., WEHNER, N., JOHNSON‐WOOD, K., YEDNOCK, T., SEUBERT, P., & SCHENK, D. (2000). Prevention and Reduction of AD‐type Pathology in PDAPP Mice Immunized with Aβ1–42. Annals of the New York Academy of Sciences. https://doi.org/10.1111/j.1749-6632.2000.tb06936.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.